Advertisement

Topics

Type 2 diabetes medicine cuts risk of CV death independent of background blood sugar control

13:03 EDT 12 Sep 2017 | Cardiovascular Business

Empagliflozin tablets reduced the risk of cardiovascular death by 38 percent in people with type 2 diabetes and established cardiovascular disease (CVD), according to a randomized, placebo-controlled trial of more than 7,000 patients. And new analyses demonstrate a similar benefit was seen in all patients, regardless of blood sugar levels at baseline or after the introduction of background treatment.

Original Article: Type 2 diabetes medicine cuts risk of CV death independent of background blood sugar control

NEXT ARTICLE

More From BioPortfolio on "Type 2 diabetes medicine cuts risk of CV death independent of background blood sugar control"

Quick Search
Advertisement
 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...